This Issue contains three SXSW-inspired musings or updates. The first, and most substantial, looks ahead to just one facet of the potential patient access challenges for MDMA-assisted therapy; the second briefly covers comments and unpublished analysis shared by Rick Doblin; and, the third looks at synthetic vs. whole-mushroom psilocybin. It also contains brief coverage of a number of other…
